Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development
– Dr. Mahableshwarkar, a Board-Certified Psychiatrist, is an experienced pharmaceutical industry leader with decades of expertise in drug development – TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024
– Amir Inamdar, Chief Medical Officer, to appear on panel discussions on June 5 and June 8 – – Ellen James, Director, Clinical Development, to present abstract titled “SPL026 (DMT fumarate) in combination with SSRIs for patients with Major Depressive Disorder” on June 6, 2024 – TORONTO–(BUSINESS
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones
– Recent U.S. $150 Million funding round lead by a syndicate of leading biopharmaceutical institutional investors supports advancement of clinical-stage programs CYB003 and CYB004 – – Received U.S. Food and Drug Administration (“FDA”) Breakthrough Therapy Designation (“BTD”) for CYB003, a
Cybin to Participate at the 27th Annual Milken Institute Global Conference
– Doug Drysdale, CEO, to appear on panel entitled “Collaborating for Improved Mental Health,” on May 8, 2024 – TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
– Publication explores structure-activity relationships (“SAR”) of a broad range of 2C-X analogs – – Innovative research led to the discovery of CYB210010, a potent and long-acting serotonin 5-HT 2 receptor agonist with favorable pharmacokinetic properties – TORONTO–(BUSINESS WIRE)– Cybin Inc.
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
– Newly issued patent expected to provide exclusivity until at least 2041 and includes claims to pharmaceutical compositions within the Company’s proprietary deuterated psilocybin analog program – – Cybin’s patent portfolio now includes more than 50 granted patents and over 170 pending applications
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced